XORTX plans Q4 2026 FDA IND filing for XRx — 026 gout trial using XORLO, targets USD 700 million U.S. market
XORTX outlined plans to submit an FDA IND in Q4 2026 for its XRx-026 gout program using XORLO. No new trial results were presented; the program is being advanced based on supportive prior results and FDA discussions. The planned XRX-OXY-102 study aims to support a future NDA by clarifying dosing behavior and clinical b